Login to Your Account



Pharma: Clinic Roundup


Monday, May 14, 2012
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal Phase III trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription